Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6824879 | 0.88 | CTNNB1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28375850 | 0.84 | HTR1B (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6432198 | 0.82 | HTR1B (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3641214 | 0.82 | HTR1B (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15842206 | 0.80 | KMT2A (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL707407 | 0.79 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30427164 | 0.79 | HTR1B (0.55) | HTR1BALDH1A1MAPTCTNNB1WNT3A | |
| SCHEMBL14135299 | 0.79 | HTR1B (0.55) | HTR1BALDH1A1MAPTCTNNB1WNT3A | |
| SCHEMBL1960994 | 0.78 | CA12 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL103577 | 0.76 | HTR1B (0.59) | HTR1BCYP3A4MAOAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-01 | — | — | US | disclosed |
| EP-4406950-A2 | LFA-1 INHIBITOR AND POLYMORPH THEREOF | Bausch + Lomb Ireland Limited (IE) | 2024-07-31 | — | — | EP | disclosed |
| EP-3715345-B1 | PREPARATION OF LFA-1 INHIBITOR | NOVARTIS AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022065962-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | 한국화학연구원 | 2022-03-31 | — | — | WO | disclosed |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3715345-A2 | PREPARATION OF LFA-1 INHIBITOR AND POLYMORPH THEREOF | Novartis AG (CH) | 2020-09-30 | — | — | EP | disclosed |
| CN-110922393-A | LFA-1 inhibitors and polymorphs thereof | 诺华股份有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20200087287-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE BIOSCIENCE INC. (US) | 2020-03-19 | — | — | US | disclosed |
| CN-109641908-A | Five-ring heterocycles simultaneously [3,4-d] pyridazinone compound, preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2019-04-16 | — | — | CN | disclosed |
| US-20180251452-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE BIOSCIENCE INC. (US) | 2018-09-06 | — | — | US | disclosed |
| EP-1481978-B1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011050175-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE CORPORATION (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050175-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | SARCODE CORPORATION (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20100010224-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7612218-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252488-A1 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | MLKL, PCSK9, CTSA | CA12 3261/4885CA1 4379/4885CA2 3095/4885 |
| US-20100010224-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | PIN4, IPO5, HLCS | CA12 3195/4885CA1 4662/4885CA2 2716/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | CA12 3195/4885CA1 4662/4885CA2 2716/4885 |
| US-20200087287-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | CA12 1898/4885CA1 1827/4885CA2 2827/4885 |
| US-20180251452-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | CA12 1898/4885CA1 1827/4885CA2 2827/4885 |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | CA12 1898/4885CA1 1827/4885CA2 2827/4885 |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | ITGB1, ITGA1, VCAM1 | CA12 3964/4885CA1 2795/4885CA2 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.